Truist Securities stays Buy on Agios Pharma (AGIO) as co seeks accelerated approval for mitapivat
Tweet Send to a Friend
Truist Securities analyst Greg Renza reiterated a Buy rating and $39.00 price target on Agios Pharma (NASDAQ: AGIO)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
